CYP2D6 testing to predict response to tamoxifen in women with breast cancer

Issa Dahabreh, Teruhiko Terasawa, Peter Castaldi, Thomas Trikalinos

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Tamoxifen, a selective estrogen receptor modulator, is the standard of care for premenopausal women with estrogen or progesterone receptor-positive breast cancer and a valid option for treating post-menopausal women. However, a substantial number of tamoxifen-treated patients relapse following surgical resection, while others remain disease-free for many years. It appears that the primary effectors of tamoxifen activity are its active metabolites, rather than tamoxifen itself. Cytochrome P450 (CYP) enzymes, CYP2D6 in particular, play a major role in the metabolism of tamoxifen to active metabolites. More than 75 germline CYP2D6 variants have been identified. A test predicting lack of response to tamoxifen could supplement information used by clinicians and patients in treatment decision-making. For example, physicians and patients may opt to switch to an alternative therapy upfront.

Original languageEnglish
Article numberecurrents.RRN1176
JournalPLoS Currents
Issue numberOCT
Publication statusPublished - 2010

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)


Dive into the research topics of 'CYP2D6 testing to predict response to tamoxifen in women with breast cancer'. Together they form a unique fingerprint.

Cite this